Why the study?
Heart failure with preserved ejection fraction has historically been resistant to pharmacological interventions, and SGLT2 inhibitors have emerged as a promising therapeutic option.
Do SGLT2 inhibitors improve functional capacity and reduce clinical events in patients with HFpEF?
Do SGLT2 inhibitors improve functional capacity and reduce clinical events in patients with HFpEF?
This systematic review confirms that SGLT2 inhibitors consistently improve functional capacity and reduce heart failure hospitalizations in patients with HFpEF, establishing them as foundational, first-line therapies.
Supports SGLT2 inhibitor use in HFpEF; confirms consistent benefits across 10 RCTs.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as a promising therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF), a condition historically resistant to pharmacological interventions. This systematic review synthesizes evidence from 10 randomized controlled trials evaluating the effects of empagliflozin and dapagliflozin on functional capacity and hospitalization outcomes in HFpEF patients. The findings consistently demonstrate significant improvements in patient-reported outcomes, such as the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and six-minute walk test (6MWT) performance, along with reductions in heart failure hospitalizations. These benefits were observed across diverse patient populations, including older adults and those with comorbidities like diabetes and chronic obstructive pulmonary disease, with a favorable safety profile. The review supports the incorporation of SGLT2 inhibitors as a central component in the management of HFpEF, offering both symptomatic relief and a reduction in clinical events.
No takes yet. Share an insight, caveat, or question.
Awais et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: